NASDAQ
Telomir Pharmaceuticals, Inc. (TELO)
♥ 594 Thanks from members
Telomir Pharmaceuticals, Inc. (TELO) exhibits mixed market sentiment, balancing long-term clinical pipeline potential—including an FDA nod for a breast cancer study and early leukemia cell death findings—against severe financial headwinds, pre-revenue status, and explicit going-concern warnings from recent SEC filings.